GMMMG Interface Prescribing
Subgroup
Agenda
9th April 2015, 1pm-3pm
HMR CCG
Room 410, Number One Riverside, Smith St. Rochdale OL16 1XU
Declarations of Interest (new declarations only)
Apologies:
ENC
th
1)
Draft Minutes of 12 March 2015
Item 1
2)
Matters Arising
Item 2g
Item 2j
a) RAG List Recommendations LMWH – awaiting GMMMG approval
b) RAG List Recommendations from January meeting – now GMMMG
approved
c) RAG List Recommendations from February meeting – awaiting
GMMMG approval
d) RAG List Recommendations from March meeting (Drugs for alcohol
dependence, Chapter 3 and 13) – comments due by 7th May
e) Antidementia drugs leaflets –now GMMMG approved
f) Chapter 10 SCP Protocol Review – on hold
g) Chapter 9 SCP Review - hydroxycarbamide
h) Chapter 5 SCP Review - colistimethate for non-CF patients
i) Chapter 4 SCP Review – ADHD Drugs
j) Chapter 6 SCP Review – Denosumab - comments due by 7th May
3) Chapter 1 RAG list review – drugs for review
a) Colesevelam – currently Green (following specialist advice)
b) Linaclotide – currently Green (following specialist initiation)
c) Mercaptopurine – currently Amber
d) Methotrexate (oral) – currently Amber
e) Metoject(R) – no status
f) Sulfasalazine – currently Amber
g) Mesalazine – no status (Green following specialist initiation on
formulary)
Item 3
h) Prednisolone enema - no status (Green following specialist initiation
on formulary)
i) Prednisolone foam - no status (Green following specialist initiation on
formulary)
j) Prednisolone suppositories - no status (Green following specialist
initiation on formulary)
k) Prucalopride - no status (Green following specialist initiation on
formulary)
l) Colestyramine - no status (Green following specialist initiation on
formulary)
m) Pancreatin (Creon® - no status (Green following specialist initiation
on formulary)
4)
Chapter 1 Shared Care Protocol review – existing guidelines
Document Title
Azathioprine and 6Mercaptopurine for Chronic
Inflammatory Bowel Disease
Azathioprine or 6 Mercaptopurine
for the treatment of chronic
inflammatory bowel disease
BNF
1
1
Organisation
Date
Review
date
In GMMMG
Format
Pennine Acute
Aug
2012
Aug-14
Yes
CMFT
Jul
2013
Jul-15
Yes
Chapter 1 Shared Care Protocol review – drugs without an SCP
Sulfasalazine
6) Chapter 8 RAG list review – drugs for review
a) Chemotherapy Drugs – currently Red
b) Abiraterone – currently Red
c) Anastrozole – currently Green (following specialist initiation)
d) Azathioprine – currently Amber (no SCP in place)
e) Interferon beta – currently Red
f) Bicalutamide – currently Amber and Green (following specialist
initiation) on list
g) Ciclosporin – currently Amber (no SCP in place)
h) Degarelix – currently Red
i) Exemestane – currently Green (following specialist initiation)
j) Flutamide – currently Amber (no SCP in place, not in formulary)
k) Fulvestrant – currently Amber for pts pre Dec 2011 and Red for
patients post Dec 2011
l) Histrelin – currently Amber (no SCP in place, not in formulary)
m) Hydroxycarbamide (thrombocythaemia or polycythaemia) – currently
Amber (no SCP in place)
n) Interferon alfa 2a & 2b – currently Red
o) Lanreotide – currently Amber (no SCP in place)
p) Letrozole – currently Green (following specialist initiation)
5)
Item 6
q) Mycophenolate – currently Amber (no SCP in place)
r) Octreotide – currently Amber (no SCP in place)
s) Sirolimus – currently Amber (no SCP in place)
t) Basiliximab – no status (Red on formulary)
u) Ofatumumab – no status (Red on formulary)
v) Interferon gamma-1b – no status
w) Canakinumab – no status (Red on formulary)
x) Glatiramer acetate – no status (Red on formulary)
y) Mifamurtide – no status (Red on formulary)
z) Natalizumab – no status (Red on formulary)
aa) Anti-thymocyte immunoglobulin – no status
bb)
Aprepitant – no status
cc) Amiofostine – no status
dd)
Betacept – no status
ee) Palifermin – no status
7) Chapter 8 Shared Care Protocol review – existing guidelines
Document Title
Fulvestrant (Faslodex®) Injection
Goserelin in the Treatment of
Breast Cancer
LEUPRORELIN (PROSTAP) for
the treatment of endometriosis,
endometrial thinning prior to
surgery and reduction of uterine
fibroids
Bicalutamide
8)
BNF
Organisation
Date
Review
date
Apr
2010
Apr
2010
8
The Christie
8
The Christie
8
Pennine Acute
Nov
2011
8
Tameside and
Glossop
Feb
2012
?
In
GMMMG
Format
Apr-12
No
Apr-12
No
Nov-14
Yes
No
Chapter 8 Shared Care Protocol review – drugs without an SCP
Hydroxycarbamide – essential thrombocythaemia or
polycythaemia
Lanreotide
Mycophenolate (transplant indications)
Octreotide
Sirolimus
Tacrolimus
Flutamide
Histrelin
9) Strontium – review of RAG status
10) Lanthanum – review of RAG status
11) Trientine – review of RAG status
Item 9
12) Ethinylestradiol for pubertal induction
13) New Drugs from NTS and Formulary Subgroup Requiring a RAG
Status
a) DuoResp® (Budesonide/formoterol) inhaler
b) Tapentadol – not for routine prescribing & FSG added to Grey list.
c) Relvar® inhaler
d) Nabilone for the treatment of chronic non cancer pain (unlicensed
indication)
e) Aclidinium/Formoterol (Duaklir® Genuair®▼) 340/12 combination
inhaler
Item 12
14) Draft Shared Care Protocols for Discussion
Ciclosporin for use in childhood nephrotic syndrome
15) Shared Care Protocols for Approval
Cinacalcet primary hyperparathyroidism
Ibandronate for breast cancer - comments due by 7th May
16) Forward work plan
17) Updates from other groups
a) Formulary Subgroup (verbal)
b) New Therapies Subgroup (verbal)
c) GMMMG (verbal)
18) AOB
Date of Next Meeting: 14th May 2015, 1pm-3pm Room 410, HMR CCG,
Number One Riverside, Smith St, Rochdale OL16 1XU
Item 14
Item
15i
Item
15ii
Item 16